XETR
1SXP
Market cap3.44bUSD
Jul 09, Last price
19.96EUR
1D
13.28%
1Q
42.57%
IPO
-36.92%
Name
SCHOTT Pharma AG & Co KgaA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||